A platform for research: civil engineering, architecture and urbanism
A platform for research: civil engineering, architecture and urbanism
Helpful Criteria When Implementing NGS Panels in Childhood Lymphoblastic Leukemia.
The development of Next-Generation Sequencing (NGS) has provided useful diagnostic, prognostic, and therapeutic strategies for individualized management of B-cell precursor acute lymphoblastic leukemia (BCP-ALL) patients. Consequently, NGS is rapidly being established in clinical practice. However, the technology's complexity, bioinformatics analysis, and the different available options difficult a broad consensus between different laboratories in its daily routine introduction. This collaborative study among Spanish centers was aimed to assess the feasibility, pros, and cons of our customized panel and other commercial alternatives of NGS-targeted approaches. The custom panel was tested in three different sequencing centers. We used the same samples to assess other commercial panels (OncomineTM Childhood Cancer Research Assay; Archer®FusionPlex® ALL, and Human Comprehensive Cancer Panel GeneRead Panel v2®). Overall, the panels showed a good performance in different centers and platforms, but each NGS approach presented some issues, as well as pros and cons. Moreover, a previous consensus on the analysis and reporting following international guidelines would be preferable to improve the concordance in results among centers. Our study shows the challenges posed by NGS methodology and the need to consider several aspects of the chosen NGS-targeted approach and reach a consensus before implementing it in daily practice. ; This study has been supported by a grant from “Fundación Unoentrecienmil”; grants from Instituto de Salud Carlos III (PI12/02417; PI16/00246; PI12/00816; PI16CIII/00026; PI16/0665); Asociación Pablo Ugarte (TPY-M 1149/13; TRPV 205/18), ASION (TVP 141/17); Fundación Sonrisa de Alex & Todos somos Iván (TVP 1324/15); Consejería de Educación, Junta de Castilla y León (SA271P18); Fondos FEDER (CIBERONC [CB16/12/00284]), Proyectos de Investigación del SACYL, GRS 1847/A/18, Generalitat Valenciana GV2019/077 and Fundación AMPILE. J.M.H.S. is supported with a research grant by FEHH (“Fundación Española de Hematología y Hemoterapia”), A.M. a grant from Junta provincial de Salamanca de la Asociación Española Contra el Cáncer (AECC), and M.M. holds the grant “Ayuda predoctoral de la Junta de Castilla y León” by the Fondo Social Europeo (JCYL-EDU/556/2019 Ph.D. scholarship). ; Sí
Helpful Criteria When Implementing NGS Panels in Childhood Lymphoblastic Leukemia.
The development of Next-Generation Sequencing (NGS) has provided useful diagnostic, prognostic, and therapeutic strategies for individualized management of B-cell precursor acute lymphoblastic leukemia (BCP-ALL) patients. Consequently, NGS is rapidly being established in clinical practice. However, the technology's complexity, bioinformatics analysis, and the different available options difficult a broad consensus between different laboratories in its daily routine introduction. This collaborative study among Spanish centers was aimed to assess the feasibility, pros, and cons of our customized panel and other commercial alternatives of NGS-targeted approaches. The custom panel was tested in three different sequencing centers. We used the same samples to assess other commercial panels (OncomineTM Childhood Cancer Research Assay; Archer®FusionPlex® ALL, and Human Comprehensive Cancer Panel GeneRead Panel v2®). Overall, the panels showed a good performance in different centers and platforms, but each NGS approach presented some issues, as well as pros and cons. Moreover, a previous consensus on the analysis and reporting following international guidelines would be preferable to improve the concordance in results among centers. Our study shows the challenges posed by NGS methodology and the need to consider several aspects of the chosen NGS-targeted approach and reach a consensus before implementing it in daily practice. ; This study has been supported by a grant from “Fundación Unoentrecienmil”; grants from Instituto de Salud Carlos III (PI12/02417; PI16/00246; PI12/00816; PI16CIII/00026; PI16/0665); Asociación Pablo Ugarte (TPY-M 1149/13; TRPV 205/18), ASION (TVP 141/17); Fundación Sonrisa de Alex & Todos somos Iván (TVP 1324/15); Consejería de Educación, Junta de Castilla y León (SA271P18); Fondos FEDER (CIBERONC [CB16/12/00284]), Proyectos de Investigación del SACYL, GRS 1847/A/18, Generalitat Valenciana GV2019/077 and Fundación AMPILE. J.M.H.S. is supported with a research grant by FEHH (“Fundación Española de Hematología y Hemoterapia”), A.M. a grant from Junta provincial de Salamanca de la Asociación Española Contra el Cáncer (AECC), and M.M. holds the grant “Ayuda predoctoral de la Junta de Castilla y León” by the Fondo Social Europeo (JCYL-EDU/556/2019 Ph.D. scholarship). ; Sí
Helpful Criteria When Implementing NGS Panels in Childhood Lymphoblastic Leukemia.
Vega-Garcia, Nerea (author) / Benito, Rocío (author) / Esperanza-Cebollada, Elena (author) / Llop, Marta (author) / Robledo, Cristina (author) / Vicente-Garcés, Clara (author) / Alonso, Javier (author) / Barragan, Eva (author) / Fernández, Guerau (author) / Hernández-Sánchez, Jesús M (author)
2020-11-26
Journal of personalized medicine
Article (Journal)
Electronic Resource
English
DDC:
710
Glyphosate in house dust and risk of childhood acute lymphoblastic leukemia in California
| DOAJ | 2023
Colony Forming Capacity of Granulocytic Progenitor in Patients with Acute Lymphoblastic Leukemia
| British Library Online Contents | 1992
Helpful Tools in Removing Meters
Wiley | 1924
mRNA‐Engineered CD5‐CAR‐γδTCD5‐ Cells for the Immunotherapy of T‐Cell Acute Lymphoblastic Leukemia
| Wiley | 2024